Immunology Case Reports

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Abstract - Immunology Case Reports (2021) Volume 4, Issue 4

Dapirolizumab pegol: A novel treatment of patients with SLE by inhibiting CD40L

CD40 ligand (CD40L) has been described as one of the key players in regulating T cell, B cell and antigen-presenting cell activity. Pre-clinical evidence and phase 1 and 2 clinical studies with anti-CD40L antibodies, such as ruplizumab and toralizuamb suggest that CD40L blockade may be efficacious in the treatment of inflammatory and autoimmune conditions. However, clinical development of these antibodies was discontinued because of significant thromboembolic events, due to Fcmediated cross linking, resulting in platelet activation. UCB and Biogen have developed Dapirolizumab pegol (DZP) which comprises of Fab fragments with a high affinity for CD40L, conjugated to polyethylene glycol (PEG) scaffolding to deliver desired pharmacokinetic characteristics 

Author(s): Farnaz Fallah-Arani,

Abstract PDF

Get the App